FINWIRES · TerminalLIVE
FINWIRES

Barclays Downgrades REGENXBIO to Equalweight From Overweight, $12 Price Target

By

REGENXBIO (RGNX) has an average rating of overweight and mean price target of $26.25, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles